Adicet Bio

ADI-270 Clin0 renal cell carcinoma; ADI-925 Clin0 multiple cancers; ADI-002 Clin0 hepatocellular carcinoma; 3 undisclosed programs RD/Clin0 multiple cancers

Adicet Bio is developing T cell therapies to treat cancer. Gamma delta T cells recognise and eliminate diseased or cancerous cells making them well suited as cancer therapies. Moreover, these cells function in a MHC-independent manner which means they can be used in non-host settings without causing graft vs. host disease reducing risk. However, gamma delta T cells comprise a small fraction of blood cells. To overcome this, Adicet is creating universal off-the-shelf genetically modified gamma delta T cells that selectively target tumors. Adicent has shown that these cells show anti-tumor activity in vitro and in vivo mouse models and are now entering clinical trials while building their broad cancer pipeline.